Literature DB >> 19330178

Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.

Andrei Iagaru1, Rabi Kundu, Hossein Jadvar, Deborah Nagle.   

Abstract

Anal squamous cell carcinoma (ASCC) is a rare cancer of the gastrointestinal tract, representing less than 5% of the digestive malignancies. The cytological and/or histological confirmation of a suspected lesion should be followed by a complete imaging evaluation to determine the extent of disease. We are presenting our experience with (18)F-FDG PET in ASCC. This is a retrospective case series of patients diagnosed and treated for ASCC at our institution(s). A total of 14 (18)F-FDG PET scans (8 for initial staging, 6 for evaluation of response to chemotherapy and radiation therapy) were performed in 8 patients (6 men, 2 women). The patients were 33-60 years old (average: 44+/-9). Our results showed that PET demonstrated the primary lesion at initial evaluation in 7 of 8 anal cancers and showed FDG- avid lymph nodes in 4 patients. Metastatic nodal involvement was confirmed by pathology in 2 patients; in the other 2 patients pathology showed reactive follicular hyperplasia. In another patient, follow-up PET demonstrated progression of disease despite treatment, prompting a change in disease management. In the remaining 5 patients with follow-up PET, the scans confirmed interval resolution of the (18)F-FDG uptake in the primary lesion, suggesting good treatment response. In conclusion, PET provides valuable diagnostic information in initial staging and evaluation of treatment response in ASCC that may significantly alter the clinical management. The emergence of the combined PET/CT scanner enhanced the accuracy of the imaging procedure in view of the precise anatomic localization of metabolic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330178

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  4 in total

1.  Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma.

Authors:  Laetitia Vercellino; Françoise Montravers; Vincent de Parades; Virginie Huchet; Khaldoun Kerrou; Pierre Bauer; Emmanuel Touboul; Jean-Noël Talbot
Journal:  Int J Colorectal Dis       Date:  2011-02       Impact factor: 2.571

2.  FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.

Authors:  F L Day; E Link; S Ngan; T Leong; K Moodie; C Lynch; M Michael; E de Winton; A Hogg; R J Hicks; A Heriot
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

Review 3.  Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis.

Authors:  Carmelo Caldarella; Salvatore Annunziata; Giorgio Treglia; Ramin Sadeghi; Narjes Ayati; Luca Giovanella
Journal:  ScientificWorldJournal       Date:  2014-02-04

4.  Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.

Authors:  Erik S Mittra; Norman Koglin; Camila Mosci; Meena Kumar; Aileen Hoehne; Khun Visith Keu; Andrei H Iagaru; Andre Mueller; Mathias Berndt; Santiago Bullich; Matthias Friebe; Heribert Schmitt-Willich; Volker Gekeler; Lüder M Fels; Claudia Bacher-Stier; Dae Hyuk Moon; Frederick T Chin; Andrew W Stephens; Ludger M Dinkelborg; Sanjiv S Gambhir
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.